AlphAIAlphAI — Financial news for AI agents
finchannel.comOCT 72 min read$MCK

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.

Original reporting
finchannel.com
Published Oct 7, 2026, 10:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout — source image
Source · finchannel.com
Decision brief

The 30-second read

$MCKBullishHigh
01

Why it matters

The transaction creates a sizable platform in infusion services, likely improving McKesson's margin profile while offering Option Care shareholders a substantial premium.

02

Market read

A major M&A deal in the healthcare sector with immediate price moves for both parties.

03

What to watch

Regulatory approval risk and potential financing constraints for McKesson could delay closing.

Relevance 9/10Novelty 9/10Timing: today

Background

McKesson, a leading pharmaceutical distributor, is expanding its specialty‑care footprint through a near‑$6 B acquisition of Option Care Health.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson announced a $1.4 B investment for a 49% stake in Option Care Health, a $5.8 B M&A transaction.

Expected impact

modest upside as investors price in the strategic acquisition

Evidence & confidence

McKesson shares already rose 0.7% on the news; the size and strategic fit suggest further buying pressure.

$OPCHNeutralMedium confidence
Context

Option Care Health shares jumped 32.7% after the acquisition offer, and the company will become privately held.

Expected impact

potential short‑term pressure as the stock is delisted after the premium is realized

Evidence & confidence

The premium has already been priced in; post‑close trading will likely see limited upside.

Market effects

Sector

Strengthens the specialty‑care and infusion‑services segment, potentially boosting related suppliers.

Regional

U.S. healthcare M&A activity may see heightened interest.

Global

Large deal size underscores continued consolidation in global health services.

Counterpoint

What could challenge this read

The premium may be excessive if integration costs rise, suggesting caution.

Key entities

  • company
    McKesson

    U.S. pharmaceutical distributor and acquirer.

  • company
    Option Care Health

    Infusion‑services provider being acquired.

  • private equity
    Clayton, Dubilier & Rice

    Current majority owner of Option Care Health.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 7
$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

wfmz.com2 min
OCT 7
$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

finance.yahoo.com2 min
OCT 7
$MCKHighAI 9/10

McKesson, private equity firm buy home infusion company, Option Care Health

McKesson Corporation and private equity firm Clayton Dubilier & Rice (CD&R) agreed to acquire Option Care Health, a home infusion company, for $5.8 billion. McKesson will invest $1.4 billion for a 49% stake, with CD&R taking 51%. The deal values Option Care Health at $32.05 per share, a 36% premium over Monday's closing price. Once completed, Option Care Health will become private and delist from Nasdaq.

managedhealthcareexecutive.com2 min